Simplify invasive candidiasis management and move your patient’s treatment journey forward
REZZAYO™ (rezafungin for injection) is a next-generation echinocandin with a once-weekly dosing schedule1
REZZAYO™ (rezafungin for injection) is a next-generation echinocandin with a once-weekly dosing schedule1
REZZAYO™ (rezafungin for injection) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data.
Limitations of Use
REZZAYO™ has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida.
Contraindications
REZZAYO™ is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins.
Warnings and Precautions
Adverse Reactions
Most common adverse reactions (incidence ≥ 5%) are hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia.
Please see full Prescribing Information for REZZAYO™ (rezafungin for injection).
REZZAYO™ (rezafungin for injection) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the
Contraindications
REZZAYO™ is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins.
Reference:1. REZZAYOTM. Prescribing information. Melinta Therapeutics, LLC; 2023.